The CDC’s Advisory Committee on Immunization Practices (ACIP) met on April 15-16, 2025. This meeting was postponed from the regularly schedule February meeting. During this 2-day meeting, ACIP voted to recommend:
- Use of Penmenvy (GSK) pentavalent MenABCWY vaccine when both MenACWY and the Bexsero (GSK) brand of MenB vaccine are recommended during the same visit;
- Inclusion of Penmenvy in the Vaccines for Children (VFC) Program;
- Expansion of the use of any age-appropriate RSV vaccine to include adults aged 50-59 years at increased risk of severe RSV disease;
- Use of chikungunya virus-like particle vaccine (Chik-VLP, Vimkunya, Bavarian Nordic) for certain travelers age 12 years and older, and laboratory workers with potential exposure to chikungunya virus;
- Addition of a precaution for use of chikungunya live attenuated vaccine (Chik-LA, Ixchiq, Valneva) in people age 65 years and older.
ACIP received an update on the current measles outbreak in the United States and reviewed preliminary estimates of influenza and COVID-19 vaccine effectiveness during the current season. The committee received information updates on the planned use of self-administered LAIV vaccine in the 2025–26 season, an updated mRNA COVID-19 vaccine, and a new monoclonal antibody product for infant RSV prevention. The group also reviewed preliminary information on potential recommendation changes for mpox, HPV, and CMV vaccines and heard updates on the work of the pneumococcal and Lyme disease vaccine workgroups.